The core mission of pharmaceutical distribution — secure, efficient and reliable healthcare delivery — provides more than 180 million patients across the United States with efficient and low-cost access to more than 4 billion prescription medicines each year. But distributors’ work does not end there.
HDA has published “A Year in Review,” which chronicles the Alliance’s 2019 activities. Highlighted accomplishments include:
With 2020 underway, HDA’s John M. Gray provided perspective on the vital role of pharmaceutical distributors and the Alliance’s policy priorities as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.
Distributors sit at the heart of the pharmaceutical supply chain, connecting 180,000 healthcare providers and pharmacies with 1,300 drug manufacturers. Through their partnerships across the industry, pharmaceutical distributors provide the more than 180 million patients who regularly take prescription medicines with safe, quick and low-cost access to more than 4 billion prescription medicines each year.
In October 2018, the SUPPORT for Patients and Communities Act was signed into law. This bipartisan legislation offered a comprehensive response to the prescription opioid abuse epidemic — its enactment marked a significant step towards advancing meaningful solutions to address this public health crisis.